Journal
JOURNAL OF BIOPHARMACEUTICAL STATISTICS
Volume 24, Issue 2, Pages 310-325Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/10543406.2013.863779
Keywords
Dose-finding; Phase I; Oncology; Continual reassessment method; Bayesian model averaging
Categories
Ask authors/readers for more resources
Many dose-finding approaches that could evaluate bivariate binary efficacy and toxicity outcomes have been proposed in recent years. In such designs, the operating characteristics with finite sample size can be greatly affected by the assumed dose-toxicity and/or dose-efficacy relationship. However, we do not have much information about a new agent we investigated at the planning stage of Phase I trials and so always face to the risk of misspecifying the true dose-toxicity and/or dose-efficacy relationship by arbitrarily and subjectively choosing skeletons. In this article, we proposed the Bayesian model averaging bivariate continual reassessment method to cope with above risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available